Pregnancy with multiple sclerosis.

Breastfeeding Delivery Disease modifying drugs Multiple sclerosis Pregnancy

Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 20 12 2019
revised: 05 05 2020
accepted: 05 05 2020
pubmed: 2 8 2020
medline: 30 7 2021
entrez: 2 8 2020
Statut: ppublish

Résumé

Multiple sclerosis (MS) is usually diagnosed between twenty and forty years of age, when people often plan to have children. A lot has been said about the effect of pregnancy on the course of MS. The individual factors responsible for the disease modifying effect of pregnancy are not well determined. Having MS neither affects the fertility or the course of pregnancy itself. During pregnancy, many women find that their symptoms stay the same or even improve. Epidural and spinal analgesia appear to be safe and in general are not contraindicated for patients with MS. The management of disease-modifying treatments (DMTs) in pregnancy is a new issue for consideration in the clinical practice. There is limited information available into the safety of DMT use during pregnancy, especially for the most recent ones. In general, discontinuation of DMTs is recommended before conception to minimize risk of fetal harm. Women with very active MS before pregnancy who stop second-line treatments may show an increase in disease activity during pregnancy. Therefore, it might be discussed to maintain patients on DMTs until pregnancy is confirmed, and sometimes throughout pregnancy, to avoid a rebound of disease activity and severe relapses during pregnancy in very active patients.

Identifiants

pubmed: 32736812
pii: S0035-3787(20)30612-3
doi: 10.1016/j.neurol.2020.05.005
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

180-194

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

S Vukusic (S)

Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation et centre de recherche, ressources et compétences sur la sclérose en plaques, hospices civils de Lyon, 69677 Bron, France; Inserm 1028 et CNRS UMR 5292, observatoire français de la sclérose en plaques, centre de recherche en neurosciences de Lyon, 69003 Lyon, France; Université de Lyon, université Claude-Bernard Lyon 1, 69000 Lyon, France; Eugène Devic EDMUS Foundation against multiple sclerosis, state-approved foundation, 69677 Bron, France.

L Michel (L)

Inserm, CIC 1414 [(centre d'investigation clinique de Rennes)], neurology, université Rennes, CHU Rennes, 35000 Rennes, France; Inserm, établissement français du sang, unité mixte de recherche (UMR) S1236, university of Rennes, Rennes, France.

S Leguy (S)

Inserm, CIC 1414 [(centre d'investigation clinique de Rennes)], neurology, université Rennes, CHU Rennes, 35000 Rennes, France.

C Lebrun-Frenay (C)

CRCSEP, CHU de Nice Pasteur 2, Université Nice Côte d'Azur UR2CA URRIS, Nice, France. Electronic address: lebrun-frenay.c@chu-nice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH